Granted Patent B2

US 12,509,559 · App. 17/772,466 · Granted Dec 30, 2025

Inventors: Anita Shukla (East Greenwich, RI); Dahlia Alkekhia (Providence, RI); Akram Abbasi (Providence, RI)

Assignee: Brown University

C08J3/075A61K47/6903C12Q1/04C08J2300/208C08J2333/26C08J2405/16

Abstract

Claims (18)

1 . A B-lactamase responsive hydrogel that releases an antibiotic in the presence of a B-lactamase producing bacteria, the hydrogel comprising:

(a) cross-linkers that are cross-linking a polymer, the crosslinkers including one or more molecules each comprising one or more β-lactams;

(b) nanoparticles encapsulated in the polymer and held encapsulated therein by the cross-linking;

(c) an antibiotic inside the nanoparticles;

wherein the hydrogel exhibits a B-lactamase-responsive degradation when contacted by the B-lactamase producing bacteria;

wherein the hydrogel does not degrade or is stable when contacted by a non-β-lactamase-producing bacteria;

wherein the nanoparticles are released from the hydrogel upon said β-lactamase-responsive degradation; and upon the release of the nanoparticles, the nanoparticles are capable of releasing the antibiotic.

2 . The hydrogel of claim 1 , wherein the hydrogel exhibits the β-lactamase-responsive degradation due to β-lactam ring hydrolysis, causing cleavage of the crosslinker when contacted by β-lactamase enzyme.

3 . The hydrogel of claim 1 , wherein the hydrogel exhibits β-lactamase-responsive degradation due to β-lactam ring hydrolysis, causing cleavage of the crosslinker when contacted by β-lactamase-producing bacteria.

4 . The hydrogel of claim 1 , wherein the polymer comprises a poly-carboxymethyl-β-cyclodextrin (PCD) or poly (ethylene glycol).

5 . A method of fabricating a β-lactamase responsive hydrogel that releases an antibiotic in the presence of a β-lactamase producing bacteria, the method comprising the step of combining a polymer with a cross-linker comprising β-lactam containing molecules, wherein the β-lactam containing molecules form cross-links between the host polymer; and

providing one or more nanoparticles during said forming of cross-links, each of the one or more nanoparticles including an antibiotic, whereby each of the one or more nanoparticles are encapsulated in cross-linked polymer;

wherein the hydrogel is operative to release the nanoparticles upon a 13 lactamase-responsive degradation of the hydrogel; and

wherein the hydrogel is operative to retain the nanoparticles embedded therein when contacted by a non-S-lactamase-producing bacteria.

6 . The hydrogel of claim 1 , wherein the hydrogel is suitable for an application to a wound, and wherein the hydrogel is stable after the application to the wound until the hydrogel is contacted by the β-lactamase-producing bacteria.

7 . The hydrogel of claim 1 , wherein the hydrogel is suitable for a prophylactic wound dressing or a prophylactic skin dressing, the dressing operative to release an antibiotic when the dressing is contacted by a β-lactamase-producing bacteria.

8 . The hydrogel of claim 1 , wherein the hydrogel does not cause an antibiotic resistance in one or more bacteria that are contacted by the hydrogel when the antibiotic is not released from the hydrogel or when the one or more bacteria do not comprise bacteria that are β-lactamase-producing bacteria.

9 . The hydrogel of claim 1 , wherein the hydrogel will provide a complete degradation of the hydrogel when the hydrogel is incubated with a culture of a β-lactamase-producing bacteria in approximately seventy-two hours; and wherein the hydrogel will remain stable over this time of seventy-two hours when incubated with a non-β-lactamase-producing bacteria.

Assignments (2)

Continuity (2)

References Cited (347)